Radiation Oncology · 2019 · 26 citations · 16 references
MedicineOncologyRadiation OncologyRadiation DosimetryRadiation SafetyTreatment PlanningIntensity-modulated RadiotherapyRadiation TherapyRadiation Treatment PlanningRadiobiological ConsiderationsThoracic Radiation CareDisease Stage AssessmentNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentRadiotherapy CombinationsRadiotherapy Patient SafetyRadiotherapy Plan EvaluationStage 3 DiseaseTotal Dose
BACKGROUND: Consistent results are lacking as regards the comparative effectiveness of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) versus conventional intensity-modulated radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Therefore, we conducted a retrospective analysis to demonstrate the role of SIB-IMRT for patients. METHODS: Patients who had histologically confirmed NSCLC, stage III disease and received thoracic IMRT between 2014 and 2016 were retrospectively reviewed. The survival, toxicities and dose to organs at risk (OAR) were compared among patients irradiated with different techniques. The SIB-IMRT plans were designed to deliver 45-59.4Gy (median: 50.4Gy) to PTV while simultaneously delivering 50-70Gy (median: 59.92Gy) to PGTV. As for conventional IMRT plans, a total dose of 50-70Gy (median: 60Gy) was delivered to PTV. RESULTS: 426 patients with stage III NSCLC were eligible for analysis, including 128 with SIB-IMRT and 298 with conventional IMRT. The SIB-IMRT group had more stage IIIB disease (69.5% vs. 53%, P = 0.002), larger planning treatment volumes (median: 504 ml vs. 402 ml, P<0.001), and a larger planning treatment volume/volume of lung ratio (median, 0.18 vs. 0.12, P<0.001). The median OS of the SIB-IMRT and conventional IMRT groups were 34.5 and 31.7 months, with the 2-year rate of 60.4 and 59%, respectively (P = 0.797). No difference in PFS, LRFS or DMFS was observed between the two techniques. Patients treated with SIB-IMRT got similar lung and esophageal toxicities versus those with conventional IMRT. CONCLUSIONS: SIB-IMRT may be an effective and safe option for patients with locally advanced NSCLC, especially for those with large mass or wide lymph node metastasis.
16
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text
Stephen G. Chun, Chen Hu, Hak Choy et al. · Journal of Clinical Oncology · 2016 · 748 citations · Full text
Clinical Features of 5,628 Primary Lung Cancer Patients
Ping Yang, Mark S. Allen, Marie Christine Aubry et al. · CHEST Journal · 2005 · 401 citations
Medicine, Oncology, Metastasis +11
Feng‐Ming Kong, Randall K. Ten Haken, Matthew J. Schipper et al. · JAMA Oncology · 2017 · 222 citations · Full text
Medicine, Nuclear Medicine, Oncology +14